Physician profile
Hazel Ramos
NPI 1669952362
$810.10
in general payments reported to CMS, 2019-2025
11 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $232 · 2023: $284 · 2024: $88.73 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.58 | 2022-2025 | |
| Stryker Corporation | $159.91 | 2023 | Hoffmann |
| Takeda Pharmaceuticals U.S.A., INC. | $62.29 | 2022-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.37 | 2022 | |
| Phathom Pharmaceuticals, INC. | $37.45 | 2024 | Voquezna |
| Janssen Biotech, INC. | $29.57 | 2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $26.20 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $21.58 | 2023 | Zinplava, Dificid, Zerbaxa |
| Ardelyx, INC. | $21.17 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $18.33 | 2025 | Zenpep |
| Celgene Corporation | $14.65 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.